Ovarian Cancer Clinical Trial
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Summary
Blood samples and Tumor tissue will be collected at certain timepoints and will be tested.
View Full Description
Full Description
Blood samples will be tested by Natera to identify residual tumor DNA for genetic changes in the tumor to potentially improve prediction of long term prognosis and guide treatment options.
View Eligibility Criteria
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis of epithelial ovarian cancer stage II-IV
Exclusion Criteria:
Insufficient tumor to perform Signatera testing; Inability to provide consent for the trial
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
Submit
There is 1 Location for this study
See Locations Near You
AHN West Penn Hospital
Pittsburgh Pennsylvania, 15224, United States
Pittsburgh Pennsylvania, 15224, United States
How clear is this clinincal trial information?